CN111138480B - Preparation method and application of tricyclohexyltin quinoline-4-formate complex - Google Patents

Preparation method and application of tricyclohexyltin quinoline-4-formate complex Download PDF

Info

Publication number
CN111138480B
CN111138480B CN201911366759.0A CN201911366759A CN111138480B CN 111138480 B CN111138480 B CN 111138480B CN 201911366759 A CN201911366759 A CN 201911366759A CN 111138480 B CN111138480 B CN 111138480B
Authority
CN
China
Prior art keywords
quinoline
tricyclohexyltin
complex
preparation
formate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201911366759.0A
Other languages
Chinese (zh)
Other versions
CN111138480A (en
Inventor
朱小明
张复兴
蒋伍玖
冯泳兰
邝代治
庾江喜
谭宇星
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hengyang Normal University
Original Assignee
Hengyang Normal University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hengyang Normal University filed Critical Hengyang Normal University
Priority to CN201911366759.0A priority Critical patent/CN111138480B/en
Publication of CN111138480A publication Critical patent/CN111138480A/en
Application granted granted Critical
Publication of CN111138480B publication Critical patent/CN111138480B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/22Tin compounds
    • C07F7/2224Compounds having one or more tin-oxygen linkages
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses a preparation method and application of tricyclohexyl tin quinoline-4-formate complex, which is a complex with the following structural formula (I)

Description

Preparation method and application of tricyclohexyltin quinoline-4-formate complex
Technical Field
The invention relates to a tricyclohexyltin quinoline-4-formate complex, a preparation method thereof and application of the complex in preparing antitumor drugs.
Background
Since Brown first discovered organotin carboxylates (CH 3 CO 2 SnPh 3 ) The synthesis, structure and biological activity research of the organotin carboxylate complex are widely focused by scientists since the biological activity of inhibiting the tumor of mice is inhibited. However, the known organotin compounds are generally highly toxic and therefore limited in application. Studies have shown that the structure, reactivity and biological activity of organotin compounds are related to both the hydrocarbon-based structure directly attached to the tin atom and the nature of the ligand. The organic tin complex structure is optimized through molecular design, so that the balance between toxicity and biological activity of the organic tin complex is regulated, and the organic tin complex is an important direction of current research. The coordination mode of tin atoms can be greatly changed by functionalizing hydrocarbon groups or ligands, thereby influencing the biology of the organotin complexActivity is one of the currently available methods. Studies have shown that the toxicity of organotin compounds is related to their relative molecular masses, with smaller relative molecular masses being more toxic and larger relative molecular masses being more bulky hydrocarbyl tin. Therefore, the novel large steric hindrance alkyl tin complex is synthesized, and the structure and the biological activity of the complex are researched, so that the complex has important research significance.
It is well known that azacyclic rings are important and common structural units of medicines, pesticides, functional materials, etc., most of which are closely related to life systems, so that studying the structure of organotin derivatives of such ligands can provide useful information not only for the disclosed anticancer mechanism, but also for the development of novel drugs as possible molecular designs. It is necessary to synthesize a novel nitrogen-containing heterocyclic organotin carboxylate compound and conduct a study on the bioactivity of the compound, the nitrogen-containing heteroatom carboxylic acid being an important carboxylic acid ligand. For example, chinese patent CN101402650B discloses an application of a dibutyl tin and quinolinecarboxylic acid complex in preparing medicines for treating gastric cancer, nasopharyngeal carcinoma, human liver cancer or leukemia.
Based on the fact that tricyclohexyl tin hydroxide is a substance with good biological activity, the invention selects tricyclohexyl tin hydroxide, and cyclohexyl has the characteristics of larger steric hindrance, larger molecular weight and the like, and reacts with ligand quinoline-4-formic acid under certain conditions to synthesize a complex with stronger inhibition activity on A549 (human lung cancer cells), hela (human cervical cancer cells) and HGC-27 (human gastric cancer cells), thereby providing a new approach for developing anticancer drugs.
Disclosure of Invention
In view of the above problems of the prior art, a first object of the present invention is to provide a tricyclohexyltin quinoline-4-carboxylate complex.
The second object of the present invention is to provide a process for preparing the above tricyclohexyltin quinoline-4-carboxylate complex.
The third object of the invention is to provide the application of the tricyclohexyltin quinoline-4-formate complex in preparing anticancer drugs.
As a first aspect of the present invention, a tricyclohexyltin quinoline-4-carboxylate complex having the following structural formula (I):
Figure 328712DEST_PATH_IMAGE001
(I)。
the tricyclohexyltin quinoline-4-formate complex is subjected to element analysis, infrared spectrum analysis and nuclear magnetic resonance spectrum analysis, and the results are as follows:
elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
As a preparation method of the tricyclohexyltin quinoline-4-formate complex, tricyclohexyltin hydroxide, quinoline-4-formic acid and anhydrous methanol serving as solvents are sequentially added into a microwave reaction tank, and microwave reaction is carried out in an air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 60-120 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex.
In a preferred embodiment of the present invention, the mass ratio of the tricyclohexyl tin hydroxide to the quinoline-4-carboxylic acid is 1 (1-1.05).
In a preferred embodiment of the invention, the solvent anhydrous methanol is added in an amount of 10-15 ml per millimole of tricyclohexyl tin hydroxide.
The application of the tricyclohexyltin quinoline-4-formate complex as the third aspect of the invention in preparing anticancer drugs.
The applicant carries out in vitro anti-tumor activity confirmation research on the complex, and confirms that the complex has certain anti-tumor biological activity, namely the application of the complex in preparing anti-tumor drugs, in particular the application in preparing anti-human lung cancer drugs, human cervical cancer drugs and human gastric cancer drugs.
The tricyclohexyltin quinoline-4-formate complex of the invention has good anticancer activity on human lung cancer cells, human cervical cancer cells, human gastric cancer cells and the like, and can be used as a raw material for preparing medicines for resisting lung cancer, cervical cancer and gastric cancer. Compared with the currently commonly used platinum anti-cancer drugs, the tricyclohexyltin quinoline-4-formate complex has the characteristics of high anti-cancer activity, low cost, simple preparation method and the like, and provides a new way for developing anti-cancer drugs.
Drawings
FIG. 1 is an IR spectrum of tricyclohexyltin quinoline-4-carboxylic acid ester complex.
FIG. 2 is a tricyclohexyltin quinoline-4-carboxylate complex 1 H NMR spectrum.
FIG. 3 is a tricyclohexyltin quinoline-4-carboxylate complex 13 C NMR spectrum.
FIG. 4 is a tricyclohexyltin quinoline-4-carboxylate complex 119 Sn NMR spectrum.
FIG. 5 is a TG-DTG curve of tricyclohexyltin quinoline-4-carboxylate complex.
Detailed Description
The present invention is further illustrated in detail by the following examples, but it should be noted that the scope of the present invention is not limited by any of these examples.
Example 1:
preparation of tricyclohexyltin quinoline-4-carboxylate complex:
tricyclohexyl tin hydroxide 0.3857 g (1 mmol), quinoline-4-formic acid 0.1735 g (1 mmol) and solvent anhydrous methanol 10 mL are sequentially added into a microwave reaction tank, and microwave reaction is carried out under the air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 60 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex. Yield: 63%, melting point: 99-101 ℃.
Elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
Example 2:
preparation of tricyclohexyltin quinoline-4-carboxylate complex:
tricyclohexyltin hydroxide 0.3846 g (1 mmol), quinoline-4-formic acid 0.1823 g (1.05 mmol) and solvent anhydrous methanol 15 mL are sequentially added into a microwave reaction tank, and microwave reaction is carried out under the air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 60 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex. Yield: 64%, melting point: 99-101 ℃.
Elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
Example 3:
preparation of tricyclohexyltin quinoline-4-carboxylate complex:
tricyclohexyl tin hydroxide 0.3848 g (1 mmol), quinoline-4-formic acid 0.1739 g (1 mmol) and solvent anhydrous methanol 12 mL are sequentially added into a microwave reaction tank, and microwave reaction is carried out under the air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 120 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex. Yield: 64%, melting point: 99-101 ℃.
Elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
Example 4:
preparation of tricyclohexyltin quinoline-4-carboxylate complex:
tricyclohexyltin hydroxide 0.7707 g (2.0 mmol), quinoline-4-formic acid 0.3468 g (2 mmol) and solvent anhydrous methanol 25mL are sequentially added into a microwave reaction tank, and microwave reaction is carried out under the air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 60 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex. Yield: 63%, melting point: 99-101 ℃.
Elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
Example 5:
preparation of tricyclohexyltin quinoline-4-carboxylate complex:
tricyclohexyltin 0.7709 g (2.0 mmol), quinoline-4-carboxylic acid 0.3549 g (2.05 mmol) and solvent anhydrous methanol 25mL are sequentially added into a microwave reaction tank, and microwave reaction is carried out under the air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 90 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex. Yield: 64%, melting point: 99-101 ℃.
Elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
Example 6:
preparation of tricyclohexyltin quinoline-4-carboxylate complex:
tricyclohexyl tin hydroxide 1.1557 g (3.0 mmol), quinoline-4-formic acid 0.5194 g (3 mmol) and solvent anhydrous methanol 30 mL are sequentially added into a microwave reaction tank, and microwave reaction is carried out under the air atmosphere at the radiation power of 800W and the temperature of 100 ℃ for 120 min. After the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex. Yield: 65%, melting point: 99-101 ℃.
Elemental analysis (C) 28 H 39 NO 2 Sn): theoretical value: c,62.24; h,7.28; n,2.59. Measurement value: c,62.28; h,7.25; n,2.54.
IR(KBr, v/cm -1 ): 2920.23 (s), 2845.00 (m), 2360.87 (s), 2335.80 (s), 1614.42 (m), 1573.91 (m), 1508.33 (m), 1448.54 (m), 1342.46 (m), 1082.07 (w), 993.34 (w), 775.38 (w), 659.66 (m), 487.99 (w), 410.84 (w)。
1 H NMR (CDCl 3 , 500 MHz) δ (ppm): 8.98 (d, J = 4 Hz, 1H), 8.84 (d, J = 8.5 Hz, 1H), 8.15 (d, J = 8 Hz, 1H), 7.92 (d, J = 4.5 Hz, 1H), 7.68 (dt, J = 55.5 Hz, J = 7.5 Hz, 2H), 2.26 - 1.44 (m, 33H)。
13 C NMR(CDCl 3 , 125 MHz) δ (ppm): 171.15, 149.98, 149.10, 138.17, 129.78, 129.34, 127.52, 126.42, 125.68, 122.52, 34.30, 31.18 (t, J = 7.5 Hz), 28.94 (t, J = 31.3 Hz), 26.88。
119 Sn NMR (CDCl 3 , 186 MHz) δ(ppm): 32.06。
Test example:
the tricyclohexyltin quinoline-4-formate complex of the invention has in vitro anticancer activity determination realized by MTT experimental method.
MTT assay:
based on the metabolic reduction of 3- (4, 5-dimethylazol-2-yl) -2,5-diArenyltetrazolium bromide. Succinate dehydrogenase in the mitochondria of living cells reduces exogenous MTT to water insoluble blue-violet crystalline Formazan (Formazan) and deposits in cells, whereas dead cells do not. Dimethyl sulfoxide (DMSO) can dissolve formazan in cells, and the optical density of characteristic wavelength can be measured by an enzyme-labeled instrument, so that the number of living cells can be indirectly reflected.
The inhibitory activity of the tricyclohexyltin quinoline-4-carboxylic acid ester complex prepared in example 1 on human lung cancer cells (A549), human cervical cancer cells (Hela), and human gastric cancer cells (HGC-27) was measured by MTT assay.
Cell lines and culture system: a549, hela, and HGC-27 cell lines were obtained from American Tissue Culture Collection (ATCC). With 10% fetal bovine serum in RPMI1640 (GIBICO) medium at 5% (volume fraction) CO 2 In vitro culture was performed in a saturated humidity incubator at 37 ℃.
The testing process comprises the following steps: the test liquid medicine (0.0625 mu mol/L-0.5 mu mol/L) is added into each hole according to concentration gradient, and 3 parallel holes are arranged for each concentration. The experiments were divided into drug test groups (with different concentrations of test agent added), control groups (with only culture fluid and cells without test agent) and blank groups (with only culture fluid and no cells and test agent). The orifice plate after the drug addition is placed at 37 ℃ and 5 percent CO 2 Culturing in an incubator for 24 hours. The activity of the control drug was determined by the method of the test sample. In the well plate after 48 hours of incubation, MTT 20uL (5 g/L in PBS) was added to each well. At 37 DEG CAfter 4h of standing, the supernatant was removed. 150uL DMSO was added to each well and the mixture was shaken for 10min to dissolve Formazan crystals. Finally, absorbance values of each well were measured at 570nm using a BioTek multifunctional microplate reader.
And (3) data processing: data processing using the GraAr Pad Prism version5.0 program, complex IC 50 Fitting is performed through a nonlinear regression model with S-shaped dose response in the program.
The IC of the human lung cancer cell (A549) cell strain, the human cervical cancer cell (Hela) cell strain and the human gastric cancer cell (HGC-27) cell strain are determined by an MTT assay 50 Values, results are shown in table 1, conclusions are: as can be seen from the data in the table, the tricyclohexyltin quinoline-4-formate complex of the invention is used as an anticancer drug, has high anticancer activity on human lung cancer, human cervical cancer and human gastric cancer, and can be used as a candidate complex of the anticancer drug.
Table 1 tricyclohexyltin quinoline-4-carboxylate complex anticancer drug in vitro activity test data.
Human lung cancer cell Human cervical cancer cell Human gastric cancer cell
Cell strain A549 Hela HGC-27
IC 50 μM 0.2404 0.1465 0.1518
The test methods of the anti-cancer activity of the tricyclohexyltin quinoline-4-formate complex prepared in the other examples on human lung cancer cells (A549), human cervical cancer cells (Hela) and human gastric cancer cells (HGC-27) by using the MTT method are the same as those of the test examples, and the test results are basically the same as those of Table 1.

Claims (4)

1. A tricyclohexyltin quinoline-4-formate complex, which is a complex of the following structural formula (I):
Figure QLYQS_1
(I)。
2. the preparation method of the tricyclohexyltin quinoline-4-formate complex according to claim 1, which is characterized in that tricyclohexyltin hydroxide, quinoline-4-formic acid and solvent anhydrous methanol are sequentially added into a microwave reaction tank, and microwave reaction is carried out in an air atmosphere at a radiation power of 800W and a temperature of 100 ℃ for 60-120 min; after the reaction is finished, naturally cooling, filtering, naturally volatilizing and crystallizing the solvent at room temperature to obtain white crystals, namely the tricyclohexyltin quinoline-4-formate complex;
the mass ratio of the tricyclohexyl tin hydroxide to the quinoline-4-formic acid is 1 (1-1.05).
3. The preparation method according to claim 2, wherein the solvent anhydrous methanol is added in an amount of 10-15 ml per millimole of tricyclohexyl tin hydroxide.
4. The use of tricyclohexyltin quinoline-4-carboxylate complex according to claim 1 for preparing anticancer drugs, wherein the cancer cells aimed at are lung cancer, cervical cancer and gastric cancer.
CN201911366759.0A 2019-12-26 2019-12-26 Preparation method and application of tricyclohexyltin quinoline-4-formate complex Active CN111138480B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201911366759.0A CN111138480B (en) 2019-12-26 2019-12-26 Preparation method and application of tricyclohexyltin quinoline-4-formate complex

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201911366759.0A CN111138480B (en) 2019-12-26 2019-12-26 Preparation method and application of tricyclohexyltin quinoline-4-formate complex

Publications (2)

Publication Number Publication Date
CN111138480A CN111138480A (en) 2020-05-12
CN111138480B true CN111138480B (en) 2023-07-14

Family

ID=70520412

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201911366759.0A Active CN111138480B (en) 2019-12-26 2019-12-26 Preparation method and application of tricyclohexyltin quinoline-4-formate complex

Country Status (1)

Country Link
CN (1) CN111138480B (en)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113105483B (en) * 2021-03-29 2022-09-06 温州大学新材料与产业技术研究院 Tricyclohexylphosphine 5-fluorouracil-1-yl acetic acid mononuclear silver complex and preparation method and application thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101353357A (en) * 2008-09-11 2009-01-28 聊城大学 Organo-tin compound, preparation and use thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101353357A (en) * 2008-09-11 2009-01-28 聊城大学 Organo-tin compound, preparation and use thereof

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
Synthesis, Characterization, and In Vitro Cytotoxicity of Triorganotin 3,5-Di-tert-butyl-4-hydroxybenzoates;Wenchao Ding等,;《Synthesis and Reactivity in Inorganic, Metal-Organic,and Nano-Metal Chemistry》;20120131;参见83页SCH.1、摘要 *
Wenchao Ding等,.Synthesis, Characterization, and In Vitro Cytotoxicity of Triorganotin 3,5-Di-tert-butyl-4-hydroxybenzoates.《Synthesis and Reactivity in Inorganic, Metal-Organic,and Nano-Metal Chemistry》.2012, *
氢键构筑网络结构的三正丁基锡羧酸酯的合成、结构及抗癌活性;邝代治等,;《无机化学学报》;20150603;参见第1113页1.2配合物的合成 *

Also Published As

Publication number Publication date
CN111138480A (en) 2020-05-12

Similar Documents

Publication Publication Date Title
CN111138480B (en) Preparation method and application of tricyclohexyltin quinoline-4-formate complex
CN111057092B (en) Tris (2-methyl-2-phenylpropyl) tin 3-aminopyrazinate complex and preparation method and application thereof
CN111138484B (en) Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyltin ] fumarate complex
CN111116636B (en) Preparation method and application of tricyclohexyltin indole-6-formate complex
CN111138477B (en) Preparation method and application of tricyclohexyltin quinoline-6-formate complex
CN111217851B (en) Preparation method and application of tricyclohexyltin indole-4-formate complex
CN111138479B (en) Tricyclohexyltin 3-methylbenzofuran-2-formate complex and preparation method and application thereof
CN111138481B (en) Preparation method and application of tricyclohexyltin indole-3-formate complex
CN111153929A (en) Preparation method and application of tricyclohexyltin 4-chlorobenzoate complex
CN111138485B (en) Preparation method and application of tricyclohexyl tin cinnamate complex
CN111138478B (en) Tricyclohexyltin quinoxaline-2-formate complex, and preparation method and application thereof
CN111057094B (en) Tris (2-methyl-2-phenylpropyl) tin benzothiophene-2-formate complex and preparation method and application thereof
CN111057093B (en) Tricyclohexyltin benzothiophene-2-formate complex and preparation method and application thereof
CN111138483B (en) Tricyclohexyltin 2-chlorothiophene-5-formate complex and preparation method and application thereof
CN111116638A (en) Tricyclohexyltin 3-methylthiophene-2-formate complex, and preparation method and application thereof
CN111138476B (en) Tris (2-methyl-2-phenylpropyl) tin 2-chlorothiophene-5-formate complex and preparation method and application thereof
CN111138482B (en) Tris (2-methyl-2-phenylpropyl) tin 5-bromo-2-furoate complex and preparation method and application thereof
CN111138487B (en) Preparation method and application of tricyclohexyltin 1-naphthoate complex
CN111057095B (en) Tricyclohexyltin 5-chloro-2-hydroxypyridine-3-formate complex and preparation method and application thereof
CN111116641B (en) Bis [ tri (2-methyl-2-phenyl) propyltin ] furan-2-formate complex and preparation method and application thereof
CN111704631B (en) Preparation method and application of bis [ tri (2-methyl-2-phenyl) propyltin ] pamoate complex
CN111087419B (en) Preparation method and application of tris (2-methyl-2-phenylpropyl) tin p-chlorobenzoate complex
CN111269260B (en) Tris (2-methyl-2-phenylpropyl) tin 3-bromothiophene-2-formate complex and preparation method and application thereof
CN111138473B (en) Tris (2-methyl-2-phenylpropyl) tin 3-methyl-thiophene-2-formate and preparation method and application thereof
CN111138475B (en) Tris (2-methyl-2-phenylpropyl) tin 3-methylbenzofuran formate complex and preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant